Clinical Trials Logo
  1. Home
  2. Epilepsy Intractable
  3. NCT02987114

A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy

Epilepsy Intractable Clinical Trial

Official title:
A Phase II, Open-label, Single-center Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy

Clinical Trial Summary

To evaluate the safety, tolerability and efficacy of oral administration of PTL101 (cannabidiol) for the treatment for pediatric intractable epilepsy.

Study will include a 4-week observation period ,12 weeks of treatment and 2 weeks of follow up.

Clinical Trial Description

This is an open-label, single-center study recruiting approximately 15 male or female pediatric (ages 2-15, inclusive) patients with, intractable epilepsy, on stable doses of antiepileptic drugs (AEDs). The study comprised of the following period: 4 weeks observation period, followed by a 2-week dose titration period, 10-week maintenance treatment period, and a 2-week follow-up of which 1 week is a tapering-off period. Seizures will be recorded by the legal guardian/caregiver in seizure diaries throughout the first 16 weeks of the study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02987114
Study type Interventional
Source PhytoTech Therapeutics, Ltd.
Contact
Status Completed
Phase Phase 2
Start date February 13, 2017
Completion date June 28, 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT03014752 - Comparison of the Effectiveness of the Outpatient Classical Ketogenic Diet and Modified Atkins Diet on Seizures Frequency, Nutritional Status and Some Biochemical Factors in Children and Adolescents With Intractable Epilepsy Phase 2/Phase 3
Terminated NCT03790436 - Betaquik as an Adjunct to Dietary Management of Epilepsy in Adults on the Modified Atkins Diet N/A
Completed NCT05503511 - Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects Phase 1
Enrolling by invitation NCT04286776 - Memory Retrieval and Encoding Investigated by Neural Stimulation N/A
Completed NCT04763070 - Ciprofloxacin in Drug-resistant Epilepsy N/A
Completed NCT03403907 - The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients N/A
Recruiting NCT04158531 - REC2Stim as a Treatment for Refractory Epilepsy in the Primary Sensorimotor Cortex. N/A
Recruiting NCT03289572 - Microgrid II - Electrocorticography Signals for Human Hand Prosthetics
Enrolling by invitation NCT05332990 - Multicenter Comparison of Interictal HFO as a Predictor of Seizure Freedom
Recruiting NCT04325360 - Effects of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Refractory Epilepsy N/A
Active, not recruiting NCT05727943 - Add-on Clioquinol in Drug-resistant Childhood Epilepsy: an Exploratory Study Phase 2
Recruiting NCT04649008 - Localizing Epileptic Networks Using MRI and iEEG Early Phase 1
Active, not recruiting NCT03916848 - Novel Network Analysis of Intracranial Stereoelectroencephalography N/A
Completed NCT03646240 - ABI-009 (Nab-rapamycin) for Surgically-Refractory Epilepsy (RaSuRE) Phase 1
Recruiting NCT03857074 - Effects of Green Light Exposure on Epileptic Spikes in Patients With Refractory Epilepsy N/A
Enrolling by invitation NCT03702127 - TMS - Intracranial Electrodes N/A
Recruiting NCT05015868 - Contribution of Genetics, Non-invasive Methods and Neuropsychology in Focal Cryptogenic Epilepsies N/A
Enrolling by invitation NCT06138808 - 5-SENSE Score Validation Study
Not yet recruiting NCT03741192 - Impact of SPEAC® System Data on Therapeutic Decisions Related to Convulsive Seizure Patient's Refractory to AEDs N/A
Enrolling by invitation NCT05248269 - Thermocoagulation in Drug Resistant Focal Epilepsy N/A